Telavant

Telavant, a subsidiary of Roivant, is developing innovative therapies to help patients with inflammatory and fibrotic diseases. The company is advancing RVT-3101 as a potential best-in-class and first subcutaneous treatment for ulcerative colitis and Crohn's disease, including for patients with predefined biomarkers who may benefit from a precision approach.